T淋巴细胞相关肿瘤免疫疗法的研究进展

发布时间：2018-02-26 08:46

本文关键词： T淋巴细胞肿瘤免疫免疫检查点疗法嵌合抗原受体T细胞免疫疗法　出处：《中国药房》2017年20期 　论文类型：期刊论文

【摘要】：目的:了解T淋巴细胞相关肿瘤免疫疗法的研究进展,以期为肿瘤的免疫治疗提供参考。方法:笔者查阅近年来国内外相关文献,就T淋巴细胞相关肿瘤免疫疗法的研究进行归纳和总结。结果:T淋巴细胞相关肿瘤免疫疗法免疫检查点疗法和嵌合抗原受体T细胞免疫疗法在临床前与临床研究中取得了良好的成效。多个肿瘤免疫治疗药物,尤其是针对细胞毒T淋巴细胞相关抗原4、程序性死亡受体1(PD-1)和PD-1配体这3个靶标的肿瘤免疫治疗药物被各研究机构和医药企业作为研发热点,其中Ipilimumab、Tremelimumab和Nivolumab已被FDA批准用于临床,且疗效显著。肿瘤免疫疗法通过诱导自身免疫系统对抗肿瘤,但多种因素影响T淋巴细胞对肿瘤的识别,造成肿瘤免疫逃逸。结论:肿瘤免疫疗法还存在一定的局限性,但其在肿瘤治疗中是一个非常有前景的研究方向,有望成为攻破肿瘤治疗的有效方法。
[Abstract]:Objective: to investigate the research progress of T lymphocyte associated tumor immunotherapy in order to provide reference for tumor immunotherapy. Results the immune checkpoint therapy and chimeric antigen receptor T cell immunotherapy for T lymphocyte associated tumor immunotherapy in preclinical and clinical studies were summarized and summarized. A number of tumor immunotherapy drugs, Especially for cytotoxic T lymphocyte associated antigens (4), programmed death receptor (PD-1) and PD-1 ligands, tumor immunotherapeutic drugs have been regarded as research and development hot spots by various research institutions and pharmaceutical enterprises. Among them, Ipilimium ababa Tremelimumab and Nivolumab have been approved for clinical use by FDA. Tumor immunotherapy can induce the autoimmune system against tumor, but many factors affect the recognition of tumor by T lymphocytes, resulting in tumor immune escape. Conclusion: tumor immunotherapy has some limitations. But it is a very promising research direction in tumor therapy, and it is expected to be an effective method to break through tumor therapy.
【作者单位】：秦皇岛市卫生学校基础医学部;唐山市工人医院药学部;
【分类号】：R730.51

【参考文献】